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Cerebrovascular diseaseAbstract Objective: The aim of the present case–control study was to determine the association
between methylene tetrahydrofolate reductase (MTHFR) C677T (rs1801133) gene polymorphism
and risk of ischemic stroke (IS) in North Indian population.
Methods: Patients with IS and age-sex matched controls were recruited from Neurology
Outpatient Department and Ward of All India Institute of Medical Sciences, New Delhi, India.
Genotyping was performed by polymerase chain reaction–restriction fragment length polymor-
phism (PCR–RFLP) method. PCR–RFLP results of nine randomly selected samples were con-
firmed by DNA sequencing. Genotypic and allelic distributions were compared between cases
and controls. Statistical analysis was done by STATA, version 13.0 software.
Results: Hypertension, diabetes, dyslipidemia, low socioeconomic status and family history of
stroke were found to have an independent association with the risk of IS after adjusting for poten-
tial confounding factors. Mean age of cases and controls were 52.83 ± 12.59 and 50.97
± 12.70 years. Multivariate logistic regression analysis showed an independent association between
MTHFR C677T gene polymorphism and risk of IS (OR 1.91; 95% CI 1.07–3.41; p= 0.028) under
dominant model [CT + TT vs. CC]. MTHFR C677T gene polymorphism was found to be indepen-
dently associated with risk of small vessel disease (SVD) after adjustment for potential confounding
factors [OR 2.51; 95% CI 1.30–4.85; p= 0.006] under the dominant model.
Conclusion: Findings of the present study suggest that MTHFR C677T gene polymorphism
might be a risk factor of IS mainly for SVD subtypes of IS in North Indian population. Further
large prospective studies are required to confirm these findings.
 2016 Production and hosting by Elsevier B.V. on behalf of Ain Shams University. This is an open access
article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).ciences,
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Stroke is a complex multi-factorial, polygenic disease resulting
from a combination of environmental, lifestyle and genetic risk
factors [1,2]. Approximately 80–90% of strokes are ischemic in
origin. The role of genetic determinants in ischemic stroke (IS)
has been demonstrated by a number of studies which include
animal model, twin and family studies [3]. Despite intensive
research efforts, the genomic etiology of IS remains elusive.
Hyperhomocysteinemia is reported to have an independent
association for the risk of vascular events including stroke
[4]. Among the genes involved in the metabolism of homocys-
teine (Hcy), methylenetetrahydrofolate reductase (MTHFR)
C677T gene polymorphism plays a pivotal role by decreasing
the activity of MTHFR and increasing Hcy levels [5,6]. Human
MTHFR gene is located on chromosome 1p36.3 [7].
MTHFR is a key enzyme in homocysteine metabolism
which catalyzes irreversibly conversion of 5,10-methyl
enetetrahydrofolate to 5-methylenetetrahydrofolate, which is
the main circulatory form of folate. This product provides
methyl group in the remethylation reaction of homocysteine
to methionine [8], which in turn is required for the synthesis
of S-adenosyl methionine (SAM) through methionine cycle
[9]. SAM is a primary methyl group donor for most of the
biological methylation reactions [10,11]. A single base pair
(677C/T) transition in the MTHFR gene changes the alanine
to valine amino acid residue which influences enzyme thermo-
lability with 30% decreased enzyme activity [12] and, in turn
resulting in elevated level of homocysteine and hypomethyla-
tion in homozygous state [13]. Several studies have shown that
an elevated level of homocysteine leads to subsequent
increased likelihood of stroke [14]. A recent study has sug-
gested that hyperhomocysteinemia is associated with SVD
and LVD subtype of stroke [15]. The MTHFR C677T poly-
morphism is suspected to induce hypomethylation which has
been found to be significantly associated with increased suscep-
tibility of IS [16].
Several studies have examined the association between
MTHFR C677T gene polymorphism and risk of IS, however,
results of these studies are inconsistent. Some reports have
shown relationship between MTHFR C677T polymorphism
and risk of IS while others have failed to replicate such associ-
ation [17]. Four studies with small sample size have been
reported from Indian population out of which three were
found to have a significant association with the risk of IS
[18–20], while one did not find significant association between
MTHFR C677T polymorphism and risk of IS [21]. To draw a
more profound conclusion, the present case–control study was
undertaken to determine the association of MTHFR C677T
(rs1801133) gene polymorphism and susceptibility to IS in
North Indian population.
2. Methods
2.1. Study participants
The study was conducted in the Department of Neurology, All
India Institute of Medical Sciences (AIIMS), New Delhi. It
was a hospital based case–control study and was completed
in 2 years (November 2012 to October 2014). A total of 450
patients having stroke symptoms were screened. Patients witha history of transient ischemic attack, fever, rheumatologic
disease, autoimmune disease, any acute or chronic infection,
computed tomography (CT) or magnetic resonance imaging
(MRI) proven hemorrhagic stroke, and a history of regular
immunosuppressive or analgesic therapies were excluded. A
total of 250 patients were recruited for the study after radiolog-
ical confirmation of IS by CT or MRI scans of the brain.
All the patients had clinical signs which were in concor-
dance with the World Health Organization definition of
stroke. The control group comprised of 250 age and sex
matched healthy individuals which mainly consisted of volun-
teers and healthy people accompanying the patients in the gen-
eral outpatient department (OPD) and were assessed by
questionnaire for verifying stroke free status (QVFSS) [22].
Informed consent was obtained from all the subjects before
collecting the information. The study was approved by the
Local Institutional Ethics Committee. The work has been car-
ried out in accordance with The Code of Ethics of the World
Medical Association (Declaration of Helsinki) for experiments
in humans.
2.2. Clinical examination
A detailed history and clinical evaluation were carried out. The
assessment of patients was done on the day of admission and
6 months after the admission. Stroke was classified using the
Trial of Org 10172 in Acute Stroke Treatment (TOAST) crite-
ria [23]. The National Institute of Health Stroke Scale
(NIHSS) was used on the day of admission for the determina-
tion of clinical severity. Definitions of variables were same as
present in our published study protocol [24].
2.3. Laboratory investigations
Four milliliter (ml) blood samples were taken in an ethylene
diamine tetra acetic acid (EDTA) vial from patients and con-
trols. Total genomic DNA was isolated from whole blood
through standard phenol–chloroform method.
2.4. Genotype determination
The genotypes of MTHFR C677T gene were detected by using
polymerase chain reaction–restriction fragment length poly-
morphism (PCR–RFLP) technique. The primers were designed
for the Single Nucleotide Polymorphism (SNP) using Primer3
online tool, (http://bioinfo.ut.ee/primer3-0.4.0/). The MTHFR
C677T region was genotyped as previously described [25].
Forward 5-GCACTTGAAGAGAAGGTGTC-3 and reverse
5-AGGACGGTGCGGTGAGAGTG-3 primers in T-100
thermal cycler (Bio-Rad). The primers were synthesized by
Imperial Sciences (Gurgaon, India) under standard conditions.
The conditions for amplification were as follows: Initial
melting step of 5 min at 94 C, followed by 35 cycles of 45 s
denaturation at 94 C, 45 s annealing at 65 C, 1 min extension
at 72 C, and a final elongation step of 10 min at 72 C.
Genotyping was performed by digesting the PCR products
by using Hinf I restriction enzyme (TAKARA BIO INC,
Japan; Code No. 1238A) and incubating at 37 C overnight.
After amplification and digestion, the products were confirmed
by agarose gel electrophoresis. The bands of 198 bp and 175 bp
were observed after digestion as seen through the UV
Figure 1 Gel image of PCR-RFLP of MTHFR C677T gene polymorphism. Loading sequence: 100 bp ladder. Lane 2–5, 7–10, 13,
16–18: C/C genotype (wild type). Lane 1, 6, 10–12, 14, 15 and 19: C/T genotype (heterozygous).
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type) genotype; two bands of 198 bp and 175 bp represented
CT (heterozygous) genotype and a single band of 175 bp rep-
resented TT (polymorphic) genotype (Fig. 1).2.5. Statistical analysis
The chi-square test was used to determine whether the allelic
frequencies were in accordance with Hardy–Weinberg equilib-
rium (HWE) or not. The conditional logistic regression analy-
sis was used to estimate odds ratio (OR) and 95% confidence
intervals (CIs) for the strength of association between
MTHFR gene polymorphism and the risk of IS. Multivariate
logistic regression was used to control the confounding effect
of demographic and risk factor variables. Tests were consid-
ered statistically significant at p< 0.05. Data were analyzed
using the STATA, version 13.0 (StataCorp. 2013. Stata
Statistical Software: Release 13. College Station, TX:
StataCorp LP).2.6. Sample size calculation
Sample size was calculated by STATA version 13.0 software.
Sample size for this study was calculated by using the frequen-
cies of cases and controls of two published studies from Indian
population in which association between MTHFR C677T
polymorphism and risk of IS was reported [18–19]. The pooled
frequency of exposure was 0.01 in controls and 0.04 in cases.
With 80% power and 5% alpha, sample size obtained was
207 cases and 207 controls. We have taken a final sample sizeTable 1 Characteristics of ischemic stroke patients and controls.
S. No. Characteristics
1. Age in years (Mean ± S.D)
2. Male/female, n
3. SBP, mmHg (Mean ± S.D)
4. DBP, mmHg (Mean ± S.D)
5. Random blood sugar (mg/dl) (Mean ± S.D)
6. Total cholesterol (mg/dl) (Mean ± S.D)
7. Triglycerides (mg/dl) (Mean ± S.D)
8. Previous stroke record, n (%)
9. Stroke in young, n (%)
Abbreviations: SBP, systolic blood pressure; DBP, diastolic blood pressuof 250 cases and 250 controls for the present study, keeping in
mind the possibility of any sample loss.
3. Results
Two-hundred fifty IS cases and two-hundred fifty age-sex
matched controls were included in the study. The mean age
of IS patients was 52.83 ± 12.59 years, in the control group
was 50.97 ± 12.70 years and both groups consisted of 203
males and 47 females. There was no statistical difference
between the age of cases and controls (p< 0.05). The clinical
characteristics and demographic variables of IS patients and
controls are presented in Tables 1 and 2 respectively. The con-
trol group was matched for age and sex, and as expected,
hypertension (cases 58.4% vs. controls 16.8%), diabetes (cases
31.6% vs. controls 10.8%), and dyslipidemia (cases 22.8% vs.
controls 5.6%) were found significantly more often in cases
than in controls (p< 0.05).
All genotype and allelic frequencies were in HWE in both
IS patients and controls. Genetic analysis for MTHFR
C677T gene polymorphism was conducted for all 250 IS cases
and 250 age and sex matched controls and is summarized in
Table 3. Conditional logistic regression analysis showed an
independent association of MTHFR C677T gene polymor-
phism with risk of IS even after adjusting the effects of poten-
tial confounding factors under dominant model [OR 1.91;
95% CI 1.07–3.41; p= 0.028] and allelic model [OR 1.44;
95% CI 1.03–2.02; p= 0.03] with the risk of IS.
In the subgroup analysis as per TOAST classification, an
independent association was observed between MTHFR
C677T polymorphism and risk of SVD, even after controllingIschemic stroke (N= 250) Controls (N= 250)
52.83 ± 12.59 50.97 ± 12.70
203/47 203/47
136.58 ± 23.67 132.06 ± 19.43
81.68 ± 12.43 81.26 ± 10.74
119.44 ± 43.68 –
168.67 ± 51.42 –
126.58 ± 64.33 –
39 (15.6) –
74 (29.6) –
re.
Table 2 Demographic and risk factor variables for ischemic stroke (IS) patients and control subjects.
Characteristics Controls (N= 250)
n (%)
Ischemic stroke (N= 250)
n (%)
Crude OR [95% CI],
p value
*Adjusted OR [95% CI],
p value
Age in years (Mean ± S.D) 52.83 ± 12.59 50.97 ± 12.70 Matched
Male/female, n 203/47 203/47
Hypertension 42 (16.8) 146 (58.4) 8.4 [4.8–14.6], <0.0001 6.2 [3.2–12], <0.0001
Diabetes 26 (10.4) 79 (31.6) 3.5 [2.1–5.7], <0.0001 2.1 [1.1–4.2], 0.02
Dyslipidemia 14 (5.6) 57 (22.8) 5.2 [2.6–10.4], <0.0001 2.4 [1.0–5.7], 0.04
Smoking 67 (26.8) 97 (38.8) 1.7 [1.1–2.5], 0.005 1.1 [0.6–1.9], 0.69
Alcohol 56 (22.4) 81 (32.4) 1.8 [1.1–2.8], 0.008 1.8 [0.9–3.5], 0.05
Myocardial infarction 4 (1.6) 17 (6.8) 5.3 [1.5–18.3], 0.008 1.8 [0.4–7.1], 0.36
Migraine with aura 8 (3.2) 10 (4) 1.2 [0.4–3.1], 0.63 1.6 [0.4–5.8], 0.40
Migraine without aura 4 (1.6) 5 (2) 1.2 [0.3–4.6], 0.33 1.3 [0.1–10.9], 0.78
Low socioeconomic status 14 (5.6) 66 (26.4) 5.0 [2.7–9.0], <0.0001 7.5 [3.0–18.2], <0.0001
High BMI 89 (35.6) 77 (30.8) 0.7 [0.4–1.0], 0.11 0.8 [0.4–1.4], 0.50
Sedentary life style 106 (42.4) 127 (50.8) 1.4 [1.0–2.1], 0.04 1.1 [0.6–1.9], 0.6
Physical activity 136 (54.4) 107 (42.8) 0.6 [0.4–0.8], 0.009 0.7 [0.4–1.3], 0.36
Family history of stroke 9 (3.6) 32 (12.8) 3.5 [1.6–7.4], 0.001 6.8 [2.2–20.9], 0.001
Family history of diabetes 28 (11.2) 48 (19.2) 1.8 [1.1–3.1], 0.015 3.1 [1.4–6.9], 0.004
Family history of hypertension 34 (13.6) 61 (24.4) 2.0 [1.2–3.1], 0.003 1.8 [0.9–3.4], 0.06
Family history of heart attack 14 (5.6) 19 (7.6) 1.4 [0.6–3.1], 0.33 1.7[0.5–5.9], 0.38
Abbreviations: IS, ischemic stroke; BMI, body mass index; OR, odds ratio; CI, confidence interval.
Conditional logistic regression analysis.
Bold values indicate the significance level of p< 0.05.
* Adjusted variables include hypertension, diabetes, dyslipidemia, smoking, family history of stroke, alcohol, sedentary life style and low
socioeconomic status.
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regression analysis. [OR 2.51; 95% CI 1.30–4.85; p= 0.006].
A significant association was observed with cardioembolic
(CE) [OR 2.34; 95% CI 1.03–5.31; p= 0.042] stroke under
the dominant model of inheritance.
4. Discussion
The present case–control study demonstrated that the C677T
polymorphism of MTHFR gene was significantly associated
with the increased risk of IS in the North Indian population.
Several studies have been conducted to determine the associa-
tion between MTHFR C677T polymorphism and IS; however,
the conclusion still remains controversial. Our results are
consistent with the recently published meta-analysis which
consisted of 38 studies involving 6310 cases and 8297 controls
which found a significant association with the risk of IS [17].
Based on ethnicity, this meta-analysis suggests a significant
association between MTHFR C677T gene polymorphism
and IS risk in both the Asian as well as Caucasian populations;
however, strength of association was higher in Asian as com-
pared to the Caucasian population. A recent meta-analysis
which included 68 case–control studies containing 7990 cases
and 6941 controls from Chinese population also confirmed
the significant association between MTHFR C677T polymor-
phism and risk of cerebrovascular diseases (OR 1.81, 95%
CI 1.6–1.9: TT vs. CC) [26]. Our findings suggest that MTHFR
C677T gene polymorphism may be used as a genetic marker
for IS in North Indian population.
Although the exact mechanism by which MTHFR poly-
morphism affects IS has not yet been fully elucidated, some
possible mechanisms have been put forward. Studies have
shown that a single base pair replacement of Cytosinenucleotide with thymine at 677 nucleotide position of MTHFR
gene influences enzyme thermolability, its decreased activity
and, in turn, the elevated level of homocysteine, an endothelial
toxin especially in the presence of low folate levels and in effect
to elevated risk of stroke [27,28]. Elevated levels of Homocys-
teine may lead to endothelial dysfunction, an early stage for
the initiation of atherosclerosis. A meta-analysis which
involved 72 case–control studies revealed an odds ratio of
1.42 for 5 lmol/l and showed an increase in the homocysteine
level. A meta-analysis suggested a mean difference in serum
homocysteine between TT and CC genotype of 2.7 mmol/L
[29]. Hyperhomocysteinemia is also linked to DNA
hypomethylation in vascular diseases [30]. A study published
by Castro et al. in 2004 demonstrated that MTHFR C677T
gene polymorphism with concomitant inadequate folate level
is associated with DNA hypomethylation and thereby
increases the risk for atherosclerosis [31]. A study has shown
that TT genotype at 677 position of MTHFR polymorphism
is linked with diminished genomic DNA methylation as com-
pared to those with wild type CC genotype (32.23 vs.
62.24 ng 5-methylcytosine/microg DNA, p< 0.0001) [32].
DNA hypomethylation is directly correlated with folate status
and inversely with homocysteine level [32]. An Asian study
demonstrated that CpG methylation in MTHFR is signifi-
cantly associated with 4.74 increased susceptibility of IS by
mediating serum folate and vitamin B-12 level [16]. Other stud-
ies have shown lower folate levels in patients with myocardial
infarction and coronary artery disease [6,19–20]. Vitamin inter-
vention may bring down the higher level of Hcy [33,34]. A
meta-analysis suggested that folic acid supplementation could
significantly reduce the risk of stroke by 18% [35]. These find-
ings explain the mechanism of association between MTHFR
polymorphism and pathogenesis of IS.
Table 3 Genotype and allelic frequencies of MTHFR C677T gene polymorphisms in IS patients and controls.
Polymorphisms LVD N= 107 SVD N= 83 CE N= 26 Others N= 34 IS N= 250 Controls
N= 250
C677T Genotype CC, n (%) 73 (68.23) 51 (61.45) 14 (53.85) 23 (67.65) 161 (64.4) 183 (73.2)
CT, n (%) 32 (29.90) 31 (37.35) 11 (42.30) 10 (29.41) 84 (33.6) 65 (26)
TT, n (%) 2 (1.87) 1 (1.20) 1 (3.85) 1 (2.94) 5 (2) 2 (0.8)
Allele C, n (%) 178 (83.18) 133 (80.12) 39 (75) 56 (82.35) 406 (81.2) 431 (86.2)
T, n (%) 36 (16.82) 33 (19.88) 13 (25) 12 (17.65) 94 (18.8) 69 (13.8)
Dominant CT + TT vs.
CC
Adjusted OR (95% CI), p
value
1.31 (0.70–2.44),
0.38
2.51 (1.30–4.85),
0.006
2.42 (0.87–6.71),
0.08
1.28 (0.51–3.21),
0.59
1.91 (1.07–3.41),
0.028
Unadjusted OR (95% CI), p
value
1.27 (0.77–2.08),
0.33
1.71 (1.01–2.89),
0.04
2.34 (1.03–5.31),
0.042
1.30 (0.60–2.82),
0.49
1.55 (1.04–2.30),
0.03
Recessive TT vs. CT
+ CC
Adjusted OR (95% CI), p
value
2.21 (0.18–26.09),
0.52
1.27 (0.06–27.08),
0.87
NE NE 1.86 (0.18–18.91),
0.59
Unadjusted OR (95% CI), p
value
2.36 (0.32–16.99),
0.39
1.51 (0.13–16.89),
0.73
4.96 (0.43–56.64),
0.19
3.75 (0.33–42.58),
0.28
2.50 (0.48–12.88),
0.27
Allelic C vs. T OR (95% CI), p value 1.26 (0.81–1.96),
0.29
1.54 (0.98–2.45),
0.06
2.08 (1.05–4.09),
0.03
1.33 (0.68–2.62),
0.39
1.44 (1.03–2.02),
0.03
Abbreviations: C, cytosine; CI, confidence interval; T, thymine; IS, ischemic stroke; LVD, large vessel disease; SVD, small vessel disease; CE, cardio embolic; OR, odds ratio; NE, not estimable (the
confidence interval could not be estimated).
Bold values indicate the significance level of p< 0.05.
*p< 0.05 is considered as statistically significant.
**Adjusted analysis was done by adjusting hypertension, diabetes, dyslipidemia, smoking, family stroke record, alcohol, sedentary life style, low economic status variables.
M
eth
y
len
etetra
h
y
d
ro
fo
la
te
red
u
cta
se
C
6
7
7
T
g
en
e
p
o
ly
m
o
rp
h
ism
a
n
d
risk
o
f
isch
em
ic
stro
k
e
3
6
3
364 A. Kumar et al.Literature suggests that susceptibility of IS risk varies in
different subtypes of IS [36]. Our stratified analysis based on
TOAST classification suggested an independent association
between MTHFR C677T gene polymorphism and risk of
SVD subtype of IS. A study also observed that MTHFR
C677T polymorphism is associated with multiple small artery
occlusion [37].
There were a few limitations in our study. First, the study
was conducted in a single hospital and the participants might
not have been the representatives from other areas. Therefore,
further large sample size and multicentric studies are needed to
confirm our findings. Second, we selected single SNP
(rs1801133) as emerging evidences have shown that the C/T
substitution is responsible for regulating the Hcy levels. Third,
we did not collect data for blood sugar, cholesterol, triglyc-
erides under controls and this study did not estimate the hcy
levels. Despite these limitations, our study provides strong evi-
dence for the independent association between MTHFR
C677T gene polymorphism and risk of IS in the North Indian
population.
5. Conclusion
In summary, the findings of the present case–control study
suggest that polymorphism in C677T position of MTHFR
gene might be a risk factor for IS in North Indian population.
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